• 1
    Pui CH,Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 605615.
  • 2
    Schrappe M,Reiter A,Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000; 95: 33103322.
  • 3
    Silverman LB,Gelber RD,Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97: 12111218.
  • 4
    Nachman JB,Sather HN,Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338: 16631671.
  • 5
    Kantarjian H,Thomas D,O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 27882801.
  • 6
    Faderl S,Jeha S,Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003; 98: 13371354.
  • 7
    Gokbuget N,Hoelzer D,Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000; 14: 13071325, ix.
  • 8
    Durrant IJ,Richards SM,Prentice HG,Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 13271352.
  • 9
    Thiebaut A,Vernant JP,Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000; 14: 13531366.
  • 10
    Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000; 14: 13671379.
  • 11
    Linker CA,Levitt LJ,O'Donnell M,Forman SJ,Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991; 78: 28142822.
  • 12
    Garcia-Manero G,Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 13811396, x–xi.
  • 13
    Kantarjian HM,O'Brien S,Smith T, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-Adriamycin-dexamethasone (VAD) regimen. Br J Haematol. 1994; 88: 94100.
  • 14
    Delannoy A,Sebban C,Cony-Makhoul P, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Leukemia. 1997; 11: 14291434.
  • 15
    Taylor PR,Reid MM,Bown N,Hamilton PJ,Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood. 1992; 80: 18131817.
  • 16
    Ferrari A,Annino L,Crescenzi S,Romani C,Mandelli F. Acute lymphoblastic leukemia in the elderly: results of 2 different treatment approaches in 49 patients during a 25-year period. Leukemia. 1995; 9: 16431647.
  • 17
    Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006; 43: 126133.
  • 18
    Kantarjian HM,Walters RS,Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990; 8: 9941004.
  • 19
    Kurtzberg J,Ernst TJ,Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005; 23: 33963403.
  • 20
    Ottmann OG,Druker BJ,Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 19651971.
  • 21
    Ottmann O,Dombret H,Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110: 23092315.
  • 22
    Gameiro P,Mortuza FY,Hoffbrand AV,Foroni L. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Haematologica. 2002; 87: 11261134.
  • 23
    Mortuza FY,Papaioannou M,Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20: 10941104.
  • 24
    Vidriales MB,Perez JJ,Lopez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003; 101: 46954700.
  • 25
    Bruggemann M,Raff T,Fiohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006; 107: 11161123.
  • 26
    Raff T,Gokbuget N,Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007; 109: 910915.